<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35116025</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Case Report: Cytomegalovirus Reactivation and Pericarditis Following ChAdOx1 nCoV-19 Vaccination Against SARS-CoV-2.</ArticleTitle><Pagination><StartPage>784145</StartPage><MedlinePgn>784145</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">784145</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2021.784145</ELocationID><Abstract><AbstractText>As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge about adverse events of SARS-CoV-2 vaccines during post-marketing surveillance. Varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation has already been reported in COVID-19 patients. In addition, adverse events after SARS-CoV-2 mRNA vaccination have also been in the context of varicella zoster virus (VZV) reactivation and directly associated with the mRNA vaccine. We present the first case of CMV reactivation and pericarditis in temporal association with SARS-CoV-2 vaccination, particularly adenovirus-based DNA vector vaccine ChAdOx1 nCoV-19 against SARS-CoV-2. After initiation of antiviral therapy with oral valganciclovir, CMV viremia disappeared and clinical symptoms rapidly improved. Since huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must be in place to assess vaccine safety that is important for the detection of any events. In the context of the hundreds of millions of individuals to be vaccinated against SARS-CoV-2, a potential causal association with CMV reactivation may result in a considerable number of cases with potentially severe complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Pl&#xfc;&#xdf;, Mese, Kowallick, Schuster, Tampe and Tampe.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pl&#xfc;&#xdf;</LastName><ForeName>Marlene</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mese</LastName><ForeName>Kemal</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Medical Microbiology and Virology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kowallick</LastName><ForeName>Johannes T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Institute of Diagnostic and Interventional Radiology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuster</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cardiology and Pneumology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tampe</LastName><ForeName>D&#xe9;sir&#xe9;e</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tampe</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Nephrology and Rheumatology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>B5S3K2V0G8</RegistryNumber><NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance></Chemical><Chemical><RegistryNumber>GCU97FKN3R</RegistryNumber><NameOfSubstance UI="D000077562">Valganciclovir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003587" MajorTopicYN="N">Cytomegalovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010493" MajorTopicYN="N">Pericarditis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077562" MajorTopicYN="N">Valganciclovir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014766" MajorTopicYN="N">Viremia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014775" MajorTopicYN="N">Virus Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ChAdOx1 nCoV-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 vaccination</Keyword><Keyword MajorTopicYN="N">cytomegalovirus</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">viral reactivation</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>4</Day><Hour>5</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35116025</ArticleId><ArticleId IdType="pmc">PMC8803643</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2021.784145</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020) 383(27):2603&#x2013;15. doi: 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Montero C, Fraile-Martinez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gomez-Lahoz AM, et al. . An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines (Basel) (2021) 9(5):433. doi: 10.3390/vaccines9050433</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9050433</ArticleId><ArticleId IdType="pmc">PMC8146241</ArticleId><ArticleId IdType="pubmed">33925526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, Bijker EM. A Guide to Vaccinology: From Basic Principles to New Developments. Nat Rev Immunol (2021) 21(2):83&#x2013;100. doi: 10.1038/s41577-020-00479-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00479-7</ArticleId><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Saati A, Al-Husayni F, Malibari AA, Bogari AA, Alharbi M. Herpes Zoster Co-Infection in an Immunocompetent Patient With COVID-19. Cureus (2020) 12(7):e8998. doi: 10.7759/cureus.8998</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.8998</ArticleId><ArticleId IdType="pmc">PMC7358933</ArticleId><ArticleId IdType="pubmed">32670724</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira A, Romao TT, Macedo YS, Pupe C, Nascimento OJM, Fellow of the American Academy of N . COVID-19 and Herpes Zoster Co-Infection Presenting With Trigeminal Neuropathy. Eur J Neurol (2020) 27(9):1748&#x2013;50. doi: 10.1111/ene.14361</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14361</ArticleId><ArticleId IdType="pmc">PMC7283788</ArticleId><ArticleId IdType="pubmed">32449248</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartari F, Spadotto A, Zengarini C, Zanoni R, Guglielmo A, Adorno A, et al. . Herpes Zoster in COVID-19-Positive Patients. Int J Dermatol (2020) 59(8):1028&#x2013;9. doi: 10.1111/ijd.15001</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijd.15001</ArticleId><ArticleId IdType="pmc">PMC7307064</ArticleId><ArticleId IdType="pubmed">32530063</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsaie ML, Youssef EA, Nada HA. Herpes Zoster May be a Marker for COVID-19 Infection During Pregnancy. Cutis (2020) 106(6):318&#x2013;20. doi: 10.12788/cutis.0133</Citation><ArticleIdList><ArticleId IdType="doi">10.12788/cutis.0133</ArticleId><ArticleId IdType="pubmed">33471879</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S, Cassaniti I, Novazzi F, Fiorina L, Piralla A, Comolli G, et al. . EBV DNA Increase in COVID-19 Patients With Impaired Lymphocyte Subpopulation Count. Int J Infect Dis (2021) 104:315&#x2013;9. doi: 10.1016/j.ijid.2020.12.051</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Balc'h P, Pinceaux K, Pronier C, Seguin P, Tadie JM, Reizine F. Herpes Simplex Virus and Cytomegalovirus Reactivations Among Severe COVID-19 Patients. Crit Care (2020) 24(1):530. doi: 10.1186/s13054-020-03252-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03252-3</ArticleId><ArticleId IdType="pmc">PMC7453668</ArticleId><ArticleId IdType="pubmed">32859241</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisen WR, Berger J, Schwartz C, Reddy A, Rai B, Wadih G, et al. . Cytomegalovirus Enterocolitis Secondary to Experimental COVID-19 Therapy. IDCases (2020) 22:e00962. doi: 10.1016/j.idcr.2020.e00962</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idcr.2020.e00962</ArticleId><ArticleId IdType="pmc">PMC7507983</ArticleId><ArticleId IdType="pubmed">32983888</ArticleId></ArticleIdList></Reference><Reference><Citation>Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of Varicella Zoster Virus After Vaccination for SARS-CoV-2. Vaccines (Basel) (2021) 9(6):572. doi: 10.3390/vaccines9060572</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9060572</ArticleId><ArticleId IdType="pmc">PMC8228758</ArticleId><ArticleId IdType="pubmed">34205861</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Jimenez P, Chicharro P, Cabrera LM, Segui M, Morales-Caballero A, Llamas-Velasco M, et al. . Varicella-Zoster Virus Reactivation After SARS-CoV-2 BNT162b2 mRNA Vaccination: Report of 5 Cases. JAAD Case Rep (2021) 12:58&#x2013;9. doi: 10.1016/j.jdcr.2021.04.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdcr.2021.04.014</ArticleId><ArticleId IdType="pmc">PMC8071473</ArticleId><ArticleId IdType="pubmed">33937467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lurz P, Luecke C, Eitel I, Fohrenbach F, Frank C, Grothoff M, et al. . Comprehensive Cardiac Magnetic Resonance Imaging in Patients With Suspected Myocarditis: The MyoRacer-Trial. J Am Coll Cardiol (2016) 67(15):1800&#x2013;11. doi: 10.1016/j.jacc.2016.02.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2016.02.013</ArticleId><ArticleId IdType="pubmed">27081020</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntmann VO, Peker E, Chandrashekhar Y, Nagel E. T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review. Circ Res (2016) 119(2):277&#x2013;99. doi: 10.1161/CIRCRESAHA.116.307974</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.116.307974</ArticleId><ArticleId IdType="pubmed">27390332</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu Mouch S, Roguin A, Hellou E, Ishai A, Shoshan U, Mahamid L, et al. . Myocarditis Following COVID-19 mRNA Vaccination. Vaccine (2021) 39(29):3790&#x2013;3. doi: 10.1016/j.vaccine.2021.05.087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.05.087</ArticleId><ArticleId IdType="pmc">PMC8162819</ArticleId><ArticleId IdType="pubmed">34092429</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Kamat I, Hotez PJ. Myocarditis With COVID-19 mRNA Vaccines. Circulation (2021) 144(6):471&#x2013;84. doi: 10.1161/CIRCULATIONAHA.121.056135</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.056135</ArticleId><ArticleId IdType="pmc">PMC8340726</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Tailor PD, Feighery AM, El-Sabawi B, Prasad A. Case Report: Acute Myocarditis Following the Second Dose of mRNA-1273 SARS-CoV-2 Vaccine. Eur Heart J Case Rep (2021) 5(8):ytab319. doi: 10.1093/ehjcr/ytab319</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytab319</ArticleId><ArticleId IdType="pmc">PMC8422333</ArticleId><ArticleId IdType="pubmed">34514306</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis Following COVID-19 Vaccination. Radiol Case Rep (2021) 16(8):2142&#x2013;5. doi: 10.1016/j.radcr.2021.05.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radcr.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8130498</ArticleId><ArticleId IdType="pubmed">34025885</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall M, Ferguson ID, Lewis P, Jaggi P, Gagliardo C, Collins JS, et al. . Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination. Pediatrics (2021) 148(3):e2021052478. doi: 10.1542/peds.2021-052478</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-052478</ArticleId><ArticleId IdType="pubmed">34088762</ArticleId></ArticleIdList></Reference><Reference><Citation>King WW, Petersen MR, Matar RM, Budweg JB, Cuervo Pardo L, Petersen JW. Myocarditis Following mRNA Vaccination Against SARS-CoV-2, a Case Series. Am Heart J Plus (2021) 8:100042. doi: 10.1016/j.ahjo.2021.100042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahjo.2021.100042</ArticleId><ArticleId IdType="pmc">PMC8349733</ArticleId><ArticleId IdType="pubmed">34396358</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmann D, Eiffert H, Schuster A. Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19. Dtsch Arztebl Int (2021) 118(31-32):546. doi: 10.3238/arztebl.m2021.0288</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.m2021.0288</ArticleId><ArticleId IdType="pmc">PMC8422910</ArticleId><ArticleId IdType="pubmed">34515024</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and Pericarditis After Vaccination for COVID-19. Jama (2021) 326(12):1210&#x2013;12. doi: 10.1001/jama.2021.13443</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.13443</ArticleId><ArticleId IdType="pmc">PMC8340007</ArticleId><ArticleId IdType="pubmed">34347001</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Leary ST, Maldonado YA. Myocarditis After SARS-CoV-2 Vaccination: True, True, and... Related? Pediatrics (2021) 148(3):e2021052644. doi: 10.1542/peds.2021-052644</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-052644</ArticleId><ArticleId IdType="pubmed">34088761</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell PT, Li JS, Wall TC, O'Connor CM, Van Trigt P, Kenney RT, et al. . Cytomegalovirus Pericarditis: A Case Series and Review of the Literature. Am J Med Sci (1995) 309(4):229&#x2013;34. doi: 10.1097/00000441-199504000-00009</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00000441-199504000-00009</ArticleId><ArticleId IdType="pubmed">7900747</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Q, Zhou Z, Yang X, Chen Y, Liu A, Zhang B, et al. . Latent Cytomegalovirus Reactivation in Patients With Liver Failure: A 10-Year Retrospective Case-Control Study, 2011-2020. Front Cell Infect Microbiol (2021) 11:642500. doi: 10.3389/fcimb.2021.642500</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.642500</ArticleId><ArticleId IdType="pmc">PMC8143188</ArticleId><ArticleId IdType="pubmed">34041042</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon MJ, Schmid DS, Hyde TB. Review of Cytomegalovirus Seroprevalence and Demographic Characteristics Associated With Infection. Rev Med Virol (2010) 20(4):202&#x2013;13. doi: 10.1002/rmv.655</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.655</ArticleId><ArticleId IdType="pubmed">20564615</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsico C, Kimberlin DW. Congenital Cytomegalovirus Infection: Advances and Challenges in Diagnosis, Prevention and Treatment. Ital J Pediatr (2017) 43(1):38. doi: 10.1186/s13052-017-0358-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-017-0358-8</ArticleId><ArticleId IdType="pmc">PMC5393008</ArticleId><ArticleId IdType="pubmed">28416012</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffiths P, Reeves M. Pathogenesis of Human Cytomegalovirus in the Immunocompromised Host. Nat Rev Microbiol (2021) 19(12):759&#x2013;73. doi: 10.1038/s41579-021-00582-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00582-z</ArticleId><ArticleId IdType="pmc">PMC8223196</ArticleId><ArticleId IdType="pubmed">34168328</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiala M, Heiner DC, Turner JA, Rosenbloom B, Guze LB. Infectious Mononucleosis and Mononucleosis Syndromes. West J Med (1977) 126(6):445&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1237626</ArticleId><ArticleId IdType="pubmed">195404</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi MK, Khanna R. Human Cytomegalovirus: Clinical Aspects, Immune Regulation, and Emerging Treatments. Lancet Infect Dis (2004) 4(12):725&#x2013;38. doi: 10.1016/S1473-3099(04)01202-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(04)01202-2</ArticleId><ArticleId IdType="pubmed">15567122</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and Human Vaccine Immune Responses. Immun Ageing (2019) 16:25. doi: 10.1186/s12979-019-0164-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-019-0164-9</ArticleId><ArticleId IdType="pmc">PMC6743147</ArticleId><ArticleId IdType="pubmed">31528180</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. . COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature (2020) 586(7830):594&#x2013;9. doi: 10.1038/s41586-020-2814-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez E, Gatell J, Moran Y, Aznar E, Buira E, Guelar A, et al. . High Incidence of Herpes Zoster in Patients With AIDS Soon After Therapy With Protease Inhibitors. Clin Infect Dis (1998) 27(6):1510&#x2013;3. doi: 10.1086/515019</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/515019</ArticleId><ArticleId IdType="pubmed">9868668</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler MS, Korsten P, Binder C, Tampe B. Correspondence on 'Interleukin-6 Receptor Blockade With Subcutaneous Tocilizumab in Severe COVID-19 Pneumonia and Hyperinflammation: Case-Control Study'. Ann Rheum Dis (2020). doi: 10.1136/annrheumdis-2020-218836</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218836</ArticleId><ArticleId IdType="pubmed">32958511</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. . Persistent Symptoms After Covid-19: Qualitative Study of 114 "Long Covid" Patients and Draft Quality Principles for Services. BMC Health Serv Res (2020) 20(1):1144. doi: 10.1186/s12913-020-06001-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12913-020-06001-y</ArticleId><ArticleId IdType="pmc">PMC7750006</ArticleId><ArticleId IdType="pubmed">33342437</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB. Long COVID or Post-Acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol (2021) 12:698169. doi: 10.3389/fmicb.2021.698169</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>